Despite a promising approach for certain leukemia patients, the path to market appears to be in question.
{
The therapy was developed at the National Cancer Institute, and Dr. Mackall said researchers did not know if a company would try to bring it to market.
https://www.nytimes.com/2017/11/20/health/cancer-immunotherapy-t-cells.html
More posts by Bruce Rychlik
Recent posts from Park Square Executive Search
